RS
Therapeutic Areas
Takeda Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Entyvio (vedolizumab) | Inflammatory Bowel Disease | Commercial |
| Ninlaro (ixazomib) | Multiple Myeloma | Commercial |
| Vyvanse (lisdexamfetamine) | ADHD | Commercial |
| Adcetris (brentuximab vedotin) | Lymphomas | Commercial |
| Takecab (vonoprazan) | Acid-related disorders | Commercial |
| TAK-981 | Solid tumors | Phase 1/2 |
| TAK-676 | Solid tumors | Phase 1 |
| TAK-573 | Solid tumors | Phase 1 |
Leadership Team at Takeda Pharmaceutical
CW
Christophe Weber
President and Chief Executive Officer
CS
Costa Saroukos
Chief Financial Officer
AP
Andrew Plump
President, Research & Development
JK
Julie Kim
Chief Medical Officer
GP
Giles Platford
President, Growth & Emerging Markets Business Unit
DE
Dirk Ehmann
President, Europe Business Unit
TA
Takeshi Aramaki
President, Japan Business Unit